|
"felip e"的相關文件
顯示項目 6-15 / 44 (共5頁)
1 2 3 4 5 > >>
每頁顯示[10|25|50]項目
| 臺大學術典藏 |
2022-08-10T02:37:38Z |
Brigatinib Versus Crizotinib in ALK Inhibitor�VNaive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial
|
Camidge D.R.; Kim H.R.; Ahn M.-J.; CHIH-HSIN YANG; Han J.-Y.; Hochmair M.J.; Lee K.H.; Delmonte A.; Garcia Campelo M.R.; Kim D.-W.; Griesinger F.; Felip E.; Califano R.; Spira A.I.; Gettinger S.N.; Tiseo M.; Lin H.M.; Liu Y.; Vranceanu F.; Niu H.; Zhang P.; Popat S. |
| 臺大學術典藏 |
2022-06-27T06:59:45Z |
Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC
|
Nishio M.; Felip E.; Orlov S.; Park K.; CHONG-JEN YU; Tsai C.-M.; Cobo M.; McKeage M.; Su W.-C.; Mok T.; Scagliotti G.V.; Spigel D.R.; Viraswami-Appanna K.; Chen Z.; Passos V.Q.; Shaw A.T. |
| 臺大學術典藏 |
2022-06-27T06:59:36Z |
Olmutinib in T790M-positive non–small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study
|
Park K.; J?nne P.A.; Kim D.-W.; Han J.-Y.; Wu M.-F.; Lee J.-S.; Kang J.-H.; Lee D.H.; Cho B.C.; CHONG-JEN YU; Pang Y.K.; Felip E.; Kim H.; Baek E.; Noh Y.S. |
| 國立成功大學 |
2022 |
Phase Ib/II study of ceritinib in combination with ribociclib in patients with ALK-rearranged non–small cell lung cancer
|
Santoro, A.;Su, W.-C.;Navarro, A.;Simonelli, M.;CH, Yang J.;Ardizzoni, Ardizzoni A.;Barlesi, F.;Hyoung, Kang J.;DiDominick, S.;Abdelhady, Abdelhady A.;Chen, X.;Stammberger, U.;Felip, E. |
| 國立成功大學 |
2022 |
Acute kidney injury in patients receiving pembrolizumab combination therapy versus pembrolizumab monotherapy for advanced lung cancer
|
Gupta, S.;Strohbehn, I.A.;Wang, Q.;Hanna, P.E.;Seethapathy, R.;Prosek, J.M.;Herrmann, S.M.;Abudayyeh, Abudayyeh A.;Malik, A.B.;Loew, S.;Carlos, Carlos C.A.;Chang, W.-T.;Beckerman, P.;Mithani, Z.;Shah, C.V.;Renaghan, A.D.;de, Seigneux S.;Campedel, L.;Kitchlu, A.;Shin, D.S.;Coppock, G.;Lumlertgul, N.;Garcia, P.;Ortiz-Melo, D.I.;Rashidi, A.;Sprangers, B.;Aggarwal, V.;Benesova, K.;Jhaveri, K.D.;Cortazar, F.B.;Weins, A.;Zuo, Y.;Mooradian, Mooradian M.J.;Reynolds, K.L.;Leaf, D.E.;Sise, M.E.;Salem, J.-E.;Bagnis, C.I.;Singh, H.;Motwani, S.S.;Murakami, N.;Tio, M.C.;Mothi, S.S.;Selamet, U.;Schmidt-Ott, K.M.;Chang, W.;Wanchoo, R.;Khanin, Y.;Hirsch, J.S.;Sakhiya, V.;Stalbow, D.;Wu, S.;Ostermann, M.;Seylanova, N.;Cennamo, A.;Rigg, A.;Shaunak, N.;Kibbelaar, Z.A.;Deshpande, P.;Seethapathy, H.S.;Lee, M.;Strohbhen, I.A.;Isik, B.;Glezerman, I.G.;Chandra, S.;Madhavan, S.M.;Owen, D.H.;Husain, M.;Mini, S.;Anand, S.;Kaghazchi, A.;Rangarajan, S.;Cherry, G.;Hsu, R.K.;Kisel, A.;Kansal, S.K.;Albert, N.;Carter, K.;Donley, V.;Young, T.;Cigoi, H.;Koessler, T.;Wauters, E.;Eijgelsheim, M.;Pagan, J.A.;Hogan, J.J.;Mamlouk, O.;Lin, J.S.;Page, V.;Short, Short S.A.P.;Gaughan, E.M.;Soler, M.J.;Garc�a-Carro, Carro C.;Bermejo, S.;Felip, E.;Mu�oz-Couselo, E.;Carreras, M.J.;Consortium, ICPi-AKI |
| 臺大學術典藏 |
2021-05-02T03:29:22Z |
Olmutinib in T790M-positive non–small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study
|
Park K.; J?nne P.A.; Kim D.-W.; Han J.-Y.; Wu M.-F.; Lee J.-S.; Kang J.-H.; Lee D.H.; Cho B.C.; CHONG-JEN YU; Pang Y.K.; Felip E.; Kim H.; Baek E.; Noh Y.S. |
| 臺大學術典藏 |
2021-04-23T05:56:29Z |
Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study
|
Tan D.S.-W.;Leighl N.B.;Riely G.J.;Chih-Hsin Yang;Sequist L.V.;Wolf J.;Seto T.;Felip E.;Aix S.P.;Jonnaert M.;Pan C.;Tan E.Y.;Ko J.;Moody S.E.;Kim D.-W.; Tan D.S.-W.; Leighl N.B.; Riely G.J.; CHIH-HSIN YANG; Sequist L.V.; Wolf J.; Seto T.; Felip E.; Aix S.P.; Jonnaert M.; Pan C.; Tan E.Y.; Ko J.; Moody S.E.; Kim D.-W. |
| 臺大學術典藏 |
2021-04-23T05:56:28Z |
Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations
|
Paik P.K.;Felip E.;Veillon R.;Sakai H.;Cortot A.B.;Garassino M.C.;Mazieres J.;Viteri S.;Senellart H.;Van Meerbeeck J.;Raskin J.;Reinmuth N.;Conte P.;Kowalski D.;Cho B.C.;Patel J.D.;Horn L.;Griesinger F.;Han J.-Y.;Kim Y.-C.;Chang G.-C.;Tsai C.-L.;Chih-Hsin Yang;Chen Y.-M.;Smit E.F.;Van Der Wekken A.J.;Kato T.;Juraeva D.;Stroh C.;Bruns R.;Straub J.;Johne A.;Scheele J.;Heymach J.V.;Le X.; Paik P.K.; Felip E.; Veillon R.; Sakai H.; Cortot A.B.; Garassino M.C.; Mazieres J.; Viteri S.; Senellart H.; van Meerbeeck J.; Raskin J.; Reinmuth N.; Conte P.; Kowalski D.; Cho B.C.; Patel J.D.; Horn L.; Griesinger F.; Han J.-Y.; Kim Y.-C.; Chang G.-C.; Tsai C.-L.; CHIH-HSIN YANG; Chen Y.-M.; Smit E.F.; van der Wekken A.J.; Kato T.; Juraeva D.; Stroh C.; Bruns R.; Straub J.; Johne A.; Scheele J.; Heymach J.V.; Le X. |
| 臺大學術典藏 |
2021-04-23T05:56:27Z |
Brigatinib Versus Crizotinib in Advanced ALK Inhibitor�VNaive ALK-Positive Non�VSmall Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial
|
Camidge D.R.;Kim H.R.;Ahn M.-J.;Chih-Hsin Yang;Han J.-Y.;Hochmair M.J.;Lee K.H.;Delmonte A.;Garc?A Campelo M.R.;Kim D.-W.;Griesinger F.;Felip E.;Califano R.;Spira A.;Gettinger S.N.;Tiseo M.;Lin H.M.;Gupta N.;Hanley M.J.;Ni Q.;Zhang P.;Popat S.; Camidge D.R.; Kim H.R.; Ahn M.-J.; CHIH-HSIN YANG; Han J.-Y.; Hochmair M.J.; Lee K.H.; Delmonte A.; Garc?a Campelo M.R.; Kim D.-W.; Griesinger F.; Felip E.; Califano R.; Spira A.; Gettinger S.N.; Tiseo M.; Lin H.M.; Gupta N.; Hanley M.J.; Ni Q.; Zhang P.; Popat S. |
| 中山醫學大學 |
2021 |
Olmutinib in T790M-positive non-small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study
|
Park, K; Janne, PA; Kim, DW; Han, JY; Wu, MF; Lee, JS; Kang, JH; Lee, DH; Cho, BC; Yu, CJ; Pang, YK; Felip, E; Kim, H; Baek, E; Noh, YS |
顯示項目 6-15 / 44 (共5頁)
1 2 3 4 5 > >>
每頁顯示[10|25|50]項目
|
